IGM Biosciences to Host Conference Call and Webcast to Review IGM-2323 Data Presented at the 62nd Annual ASH Meeting
IGM Biosciences, a clinical-stage biotechnology firm, will host a conference call and live audio webcast on December 5, 2020, at 2:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
IGM Biosciences, a clinical-stage biotechnology firm, will host a conference call and live audio webcast on December 5, 2020, at 2:00 p.m. ET. This event follows the first clinical data presentation of IGM-2323 from their Phase 1 trial at the 62nd American Society of Hematology Annual Meeting. Interested parties can access the call by dialing (866) 649-1996 or (409) 217-8769, using conference ID 1141638. The call will also be available via a live webcast on their website, with a replay accessible for 90 days afterward.
Details
News Market Reaction – IGMS
The recorded move for IGMS in the trading session of this news was -1.33%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the Company will host a conference call and live audio webcast on Saturday, December 5, 2020, at 2:00 p.m. ET. The event will take place following a poster presentation featuring the first clinical data from the Company’s Phase 1 trial evaluating IGM-2323 at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.
The conference call may be accessed by dialing (866) 649-1996 (domestic) or (409) 217-8769 (international) and referring to conference ID 1141638. A live webcast of the presentation will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.
Contact:
Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.